Benefits
One small trial (n=16) reported greater strength gains but no muscle mass gain
A small RCT randomized 16 healthy men to resistance training (RT) alone or RT + ursolic acid 450 mg/day for 8 weeks. Maximal isokinetic knee extension and flexion strength rose more in the ursolic acid group than in the training-only group, and serum irisin and IGF-1 were higher in the ursolic acid group. Irisin is a myokine that activates browning of white fat. Lean body mass did not increase significantly in either group, so no muscle was added. With 7 men in one arm and 9 in the other at a single centre, and four strength measures plus several blood markers tested, the result is fragile, and no one has replicated it.
Larger trials failed to confirm muscle/strength benefits
A larger RCT in 54 healthy adults given 500 mg/day loquat leaf extract (delivering ~51 mg UA) for 12 weeks found no differences in muscle strength, mass or physical performance versus placebo. Another RCT in 22 active men on a high-protein diet + RT given 400 mg/day UA found no additional effect on muscle strength or mass beyond what training plus protein achieved. A 2024 systematic review and meta-analysis pooling six ursolic acid trials at 50 to 450 mg/day found no significant effect on lean body mass or body fat percentage either. Net: the controlled trials show no meaningful effect on muscle or body-composition outcomes.
Mouse data showed dramatic effects (poor translation to humans)
Mouse studies showed UA decreased adiposity, glucose intolerance, and fatty liver disease while increasing skeletal muscle mass and brown fat in diet-induced obese mice. Striking results drove massive clinical interest, but human translation has been disappointing. Possible reasons: poor oral bioavailability in humans, dose-effect mismatches, species-specific muscle anabolism mechanisms. Important reminder of the preclinical-clinical translation gap.
Anti-inflammatory and antioxidant signalling in cells and animals, not confirmed in people
UA inhibits NF-κB, reduces TNF-α, IL-6, and COX-2 expression in vitro and animal models. Antioxidant via Nrf2 pathway activation. A trial that measured blood cytokines in people taking ursolic acid found no change: 27 healthy men on 400 mg/day for 8 weeks alongside resistance training showed no difference in TNF-α, IL-6 or IL-10 versus placebo. A smaller trial in 22 low-activity men reported lower CRP, IL-6 and TNF-α over 8 weeks. So the human picture is one null result and one small positive, not a settled effect, and the metabolic syndrome claim is contradicted by a trial in 26 postmenopausal women that found no improvement in the metabolic syndrome profile.
Metabolic effects seen in mice, pooled human trials null
In animals, UA increased uncoupling protein 1 (UCP1) expression, brown fat mass, and energy expenditure, which is what drove interest in it for obesity. A 2017 systematic review screened 63 studies and included 17 on ursolic acid, adiposity, energy expenditure and muscle mass, but its literature search ended in December 2015 and most of the included work was in mice. Since then, a 2024 meta-analysis of six human trials found that 50 to 450 mg/day changed none of eleven cardiometabolic measures: body weight, BMI, waist circumference, body fat percentage, lean body mass, systolic and diastolic blood pressure, fasting glucose, insulin, triglycerides and HDL.
Mechanism of action
IGF-1/Akt/mTOR pathway activation (mouse muscle)
In mouse muscle, UA promotes hypertrophy via IGF-1 receptor signaling → Akt phosphorylation → mTORC1 activation → S6K1 → protein synthesis. It also suppresses atrophy genes (atrogin-1, MuRF-1). The pathway is real in mice; translation to humans appears blunted or absent at clinically achievable doses.
Brown fat induction via UCP1 (mouse)
UA increases brown adipose tissue (BAT) markers including uncoupling protein 1 (UCP1), triggering thermogenesis. Combined with skeletal muscle hypertrophy effect, drove obesity-prevention enthusiasm in animal models. Human BAT response to oral UA has not been demonstrated.
Irisin elevation (a blood marker, small human evidence)
Two small trials in men reported higher serum irisin when ursolic acid was taken alongside resistance training. Irisin is a myokine linked in animals to browning of subcutaneous white fat. It is a blood marker rather than an outcome anyone feels, and the larger trials that measured muscle mass, body fat and physical performance found no benefit, so the step from a raised irisin level to a measured benefit in people is unproven.
Anti-inflammatory: NF-κB inhibition
UA blocks IκB phosphorylation and degradation, preventing NF-κB nuclear translocation. Reduces TNF-α, IL-1β, IL-6 production. Mechanism comparable to many other anti-inflammatory triterpenes (boswellic acids, betulinic acid). These are cell and animal findings, and the concentrations used in them have not been shown to be reached in human tissue after an oral dose. In people the results are mixed: a trial in 27 healthy men taking 400 mg/day for 8 weeks found no change in TNF-α, IL-6 or IL-10, while a smaller trial in 22 men reported lower CRP, IL-6 and TNF-α.
Clinical trials
Randomized controlled trial (Bang HS, Seo DY, Chung YM, Oh KM, Park JJ, Arturo F, Jeong SH, Kim N, Han J 2014, Korean J Physiol Pharmacol 18(5):441-446, doi:10.4196/kjpp.2014.18.5.441).
16 healthy male participants (mean age 29.4 years, BMI 27.1) randomly assigned to resistance training alone (RT n=7) or RT + UA (RT+UA n=9) for 8 weeks. UA dose 450 mg/day (3x150 mg).
Maximal isokinetic strength increased significantly more in the RT+UA group than in the RT-only group, on group by time interaction tests for right and left knee extension and flexion, and serum IGF-1 and irisin were reported as higher in the RT+UA group. Lean body mass did not increase significantly in either group. Body fat percentage fell within the RT+UA arm, with no between-group test reported for it. The authors concluded that ursolic acid induced elevation of serum irisin may be useful for enhancing skeletal muscle strength during resistance training. Significant limitations: very small sample (n=16 total, 7 vs 9), short duration, single-center, no published replication. Frequently cited as the 'positive UA trial' but the evidence base is fragile.
Randomized double-blind placebo-controlled trial (Cho YH, Lee SY, Kim CM, Kim ND, Choe S, Lee CH, Shin JH 2016, Evid Based Complement Alternat Med 2016;2016:4301621, doi:10.1155/2016/4301621, PMID 27999607). NCT02401113.
54 healthy adults randomized to 500 mg/day loquat leaf extract (delivering 50.94 mg ursolic acid) or placebo for 12 weeks. Outcomes: peak torque/body weight at 60° knee extension, handgrip strength, skeletal muscle mass, physical performance, metabolic parameters at baseline, 4 weeks, 12 weeks.
No differences in muscle strength, muscle mass or physical performance between the loquat extract and placebo groups at any time point. One secondary subgroup result went the other way: right handgrip strength in the women taking the extract was better than control (p=0.047). The authors called for further work to determine the optimal dose and duration. Counters small positive trials and is the largest, longest, most rigorous human UA trial to date with negative outcome on the primary muscle endpoints.
Randomized double-blind placebo-controlled trial (Lobo PCB, Vieira IP, Pichard C, Marques BS, Gentil P, da Silva EL, Pimentel GD 2021, Clinical Nutrition 40(2):581-589, doi:10.1016/j.clnu.2020.06.004, PMID 32593524).
22 young men randomized to control + RT (CON, n=12, 400 mg/day placebo) or UA + RT (UA, n=10, 400 mg/day UA) for 8 weeks. Both groups consumed ~1.6 g/kg protein and performed identical RT program.
Both groups showed significant increases in body weight and BMI from training/diet effect. No additional effect of ursolic acid on muscle strength or mass beyond what resistance training plus a high-protein diet alone achieved. The authors concluded that ursolic acid had no synergic effect on muscle strength and mass in response to resistance training in physically active men consuming a high-protein diet. Most well-controlled trial with directly relevant population (RT + adequate protein) and clearly negative result.